Quidel shareholders approve $6B deal to buy Ortho

By LabPulse.com staff writers

May 17, 2022 -- Quidel shareholders have approved the company's deal to buy Ortho Clinical Diagnostics. The acquisition is expected to close on May 27.

Quidel and Ortho announced the deal in December 2021, in which Quidel would acquire Ortho for an equity value of $6 billion. The deal would unite two large providers of in vitro diagnostics and has been promoted as one of the largest acquisitions in diagnostics of 2021.

The deal is expected to particularly affect the market for point-of-care diagnostics. Quidel is known for innovation and distribution in near-patient channels while Ortho is known for large, international clinical laboratories and a reputation for service.

Quidel projects record Q1 for 2022
Quidel expects revenue increases for the first quarter of the 2022 fiscal year over the previous year, which the company is calling a record quarter.
Quidel reports full-year gains as Q4 sales slip
Diagnostic testing firm Quidel reported overall revenue growth for the company's full 2021 fiscal year, despite a decline in sales in the fourth quarter....
Quidel forecasts Q4 2021 revenues
Quidel recently reported total revenues the company expects for the fourth quarter of the 2021 fiscal year, which the company called "outstanding and...
How will the Quidel, Ortho deal impact the point-of-care market?
A prediction that Quidel would buy Ortho Clinical Diagnostics a few years ago would have been greeted with incredulity, but COVID-19 has changed a lot...
Quidel inks deal to buy Ortho
Quidel has signed a definitive agreement to acquire Ortho Clinical Diagnostics for an equity value of approximately $6 billion.

Copyright © 2022 LabPulse.com

Last Updated bc 5/17/2022 11:07:41 AM